Boston, MA -- (SBWIRE) -- 03/25/2014 -- Belgium continues along the path of recovery. It is a European hub for clinical trials, new drug development and niche research, which attracts the attention of multinational firms. Even though per capita spending on pharmaceuticals is relatively high, it is subjected to continual downward pressure - creating opportunities for growth for manufacturers of generic drugs. In other words, economic agendas mean that the government will have little choice but to promote the use of generic drugs via methods other than patient information campaigns that have been launched in the past, if it is to comply with the fiscal deficit target imposed by the EU. Thus, there is not only room for the increased uptake of generic drugs following patent expiry but it will also become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies, which is increasingly important as developed states reform their healthcare systems over the medium term. Key obstacles include prescribers' brand loyalty, pay-to-delay deals, the near-universal unpopularity of commodity generics and a lack of perfect competition in the pharmaceutical sector.

View Full Report Details and Table of Contents

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2014
- Thailand Pharmaceuticals & Healthcare Report Q2 2014
- Lebanon Pharmaceuticals & Healthcare Report Q2 2014
- Japan Pharmaceuticals & Healthcare Report Q2 2014
- Australia Pharmaceuticals & Healthcare Report Q2 2014
- Oman Pharmaceuticals & Healthcare Report Q2 2014